Evidence map›Paper›PMID 35903090›Full record

ReviewFrontiers in immunology2022

Immune-Protective Formulations and Process Strategies for Improved Survival and Function of Transplanted Islets.

Yannan Shi, Ying-Zheng Zhao, Zhikai Jiang, Zeqing Wang, Qian Wang, Longfa Kou, Qing Yao

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Oxygen dynamics and delivery strategies to enhance beta cell replacement therapy.American journal of physiology. Cell physiology · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Advanced therapy to cure diabetes: mission impossible is now possible?Frontiers in cell and developmental biology · 2024
    Review
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yannan ShiSchool of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.
Ying-Zheng ZhaoSchool of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.
Zhikai JiangThe Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Zeqing WangSchool of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.
Qian WangSchool of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.
Longfa KouThe Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Qing YaoSchool of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 1 diabetes (T1D) is an autoimmune disease caused by the immune system attacking and destroying insulin-producing β cells in the pancreas. Islet transplantation is becoming one of the most promising therapies for T1D patients. However, its clinical use is limited by substantial cell loss after islet infusion, closely related to immune reactions, including instant blood-mediated inflammatory responses, oxidative stress, and direct autoimmune attack. Especially the grafted islets are not only exposed to allogeneic immune rejection after transplantation but are also subjected to an autoimmune process that caused the original disease. Due to the development and convergence of expertise in biomaterials, nanotechnology, and immunology, protective strategies are being investigated to address this issue, including exploring novel immune protective agents, encapsulating islets with biomaterials, and searching for alternative implantation sites, or co-transplantation with functional cells. These methods have significantly increased the survival rate and function of the transplanted islets. However, most studies are still limited to animal experiments and need further studies. In this review, we introduced the immunological challenges for islet graft and summarized the recent developments in immune-protective strategies to improve the outcomes of islet transplantation.

Indexed as

Diabetes Mellitus, Type 1Insulin-Secreting CellsIslets of Langerhans TransplantationAnimalsBiocompatible MaterialsOxidative StressBiocompatible Materialsbiomaterialscell therapyimmune reactionsislet encapsulationislet transplantation

Identifiers

PMID35903090
PMCPMC9315421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.